References
[1] Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyopathy: the future of treatment. Eur J Heart Fail 2020;22(2):228-40.
[2] Ozawa K, Funabashi N, Takaoka H, Kobayashi Y. Successful MACE risk stratification in hypertrophic cardiomyopathy patients using different 2D speckle-tracking TTE approaches. Int J Cardiol. 2017. 228: 1015-1021.
[3] Lorenzini M, Anastasiou Z, O’Mahony C, et al. Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. JAMA Cardiol. 2020. 5(1): 73-80.
[5] Flenner F, Jungen C, Küpker N, et al. Translational investigation of electrophysiology in hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2021. 157: 77-89.
[6] Huurman R, Schinkel A, van der Velde N, et al. Effect of body surface area and gender on wall thickness thresholds in hypertrophic cardiomyopathy. Neth Heart J. 2020. 28(1): 37-43.
[7] McLELLAN AJ, Ellims AH, Prabhu S, et al. Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. J Cardiovasc Electrophysiol. 2016. 27(5): 571-80.
[8] Smith ED, Tome J, Mcgrath R, et al. Exercise hemodynamics in hypertrophic cardiomyopathy identify risk of incident heart failure but not ventricular arrhythmias or sudden cardiac death. Int J Cardiol. 2019. 274: 226-231.
[9] Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342(24):1778-85.
[10] Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014. 35(39): 2733-79.
[11] Musumeci B, Tini G, Russo D, et al. Left Ventricular Remodeling in Hypertrophic Cardiomyopathy: An Overview of Current Knowledge. J Clin Med. 2021. 10(8).
[12] Losi MA, Imbriaco M, Canciello G, Pacelli F, Di Nardo C, Lombardi R, et al. Left ventricular mass in hypertrophic cardiomyopathy assessed by 2d-echocardiography: validation with magnetic resonance imaging. J Cardiovasc Transl Res 2020;13(2):238-44.
[13] Losi MA, Imbriaco M, Canciello G, et al. Left Ventricular Mass in Hypertrophic Cardiomyopathy Assessed by 2D-Echocardiography: Validation with Magnetic Resonance Imaging. J Cardiovasc Transl Res. 2020. 13(2): 238-244.
[14] Sreedharan S, Mathew A, Paul Z, et al. Changes in Left Ventricular Mass and Cardiovascular Risk Factors after Kidney Transplantation. Saudi J Kidney Dis Transpl. 2020. 31(5): 1006-1013.
[15]Beydoun MA, Shaked D, Hossain S, et al. Red cell distribution width, anemia and their associations with white matter integrity among middle-aged urban adults. Neurobiol Aging. 2021. 105: 229-240.
[16] Tonelli M, Sacks F, Arnold M, Moye L, Davis B, Pfeffer M, et al. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation 2008;117(2):163-8.
[17] Ulrich A, Wharton J, Thayer TE, Swietlik EM, Assad TR, Desai AA, et al. Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. Eur Respir J 2020;55(2):1901486.
[18] Xanthopoulos A, Papamichalis M, Zajichek A, Milinovich A, Kattan MW, Skoularigis J, et al. In-hospital red blood cell distribution width change in patients with heart failure. Eur J Heart Fail 2019;21(12):1659-61.
[19] Yang HJ, Liu X, Qu C, Shi SB, Liang JJ, Yang B. Usefulness of red blood cell distribution width to predict heart failure hospitalization in patients with hypertrophic cardiomyopathy. Int Heart J 2018;59(4):779-85.
[20] Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57(6):450-8.
[21] Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7(2):79-108.
[22] Nakatani S, Marwick TH, Lever HM, Thomas JD. Resting echocardiographic features of latent left ventricular outflow obstruction in hypertrophic cardiomyopathy. Am J Cardiol 1996;78(6):662-7.
[23] DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44(3):837-45.
[24] Zhu L, Wang J, Wang Y, Jia L, Sun K, Wang H, et al. Plasma uric acid as a prognostic marker in patients with hypertrophic cardiomyopathy. Can J Cardiol 2015;31(10):1252-8.
[25] Meng XB, Wang WY, Zhang K, Qi Y, An SM, Wang SY, et al. Value of N-terminal pro-B-type natriuretic peptide on long-term outcome of patients with hypertrophic cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi 2018;46(3):192-7. (in Chinese)
[26] Hasler S, Manka R, Greutmann M, Gämperli O, Schmied C, Tanner FC, et al. Elevated high-sensitivity troponin T levels are associated with adverse cardiac remodelling and myocardial fibrosis in hypertrophic cardiomyopathy. Swiss Med Wkly 2016;146:w14285.
[27] Stanzani G, Cowlam R, English K, Connolly DJ. Evaluation of red blood cell distribution width in cats with hypertrophic cardiomyopathy. J Vet Cardiol 2015;17:S233-43.
[28] Viswanath D, Hegde R, Murthy V, Nagashree S, Shah R. Red cell distribution width in the diagnosis of iron deficiency anemia. Indian J Pediatr 2001;68(12):1117-9.
[29] D’Alessandro A, Blasi B, D’Amici GM, Marrocco C, Zolla L. Red blood cell subpopulations in freshly drawn blood: application of proteomics and metabolomics to a decades-long biological issue. Blood Transfus 2013;11(1):75-87.
[30] Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006;47:C19-31.
[31] Okonko DO, Marley SB, Anker SD, Poole-Wilson PA, Gordon MY. Suppression of erythropoiesis in patients with chronic heart failure and anaemia of unknown origin: evidence of an immune basis. Int J Cardiol 2013;166(3):664-71.
[32] Chen L, Li Z, Li Y, Xue J, Chen P, Yan S, et al. Red cell distribution width and inappropriateness of left ventricular mass in patients with untreated essential hypertension. PLoS One 2015;10(3):e0120300.
[33] Gromadziński L, Januszko-Giergielewicz B, Pruszczyk P. Red cell distribution width is an independent factor for left ventricular diastolic dysfunction in patients with chronic kidney disease. Clin Exp Nephrol 2015;19(4):616-25.
[34] Yao HM, Wang XL, Peng X, Chen SY, Wan X, Zuo W, et al. Increased red blood cell distribution width might predict left ventricular hypertrophy in patients with atrial fibrillation. Medicine (Baltimore). 2020;99(37):e22119.
[35] Tse G, Yan BP, Chan YW, Tian XY, Huang Y. Reactive oxygen species, endoplasmic reticulum stress and mitochondrial dysfunction: the link with cardiac arrhythmogenesis. Front Physiol 2016;7:313.